Kim M Linton

15PUBLICATIONS
137CO-AUTHORS
Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL.

|Jan 06, 2026
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

|Sep 08, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

|Sep 08, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli

|Jun 05, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.

Alexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton

|Jan 27, 2025
Frontline treatment of follicular lymphoma: what will it take to change current practice?

Emmanuel Bachy, Kim Linton

Pageof 3

Frequent Collaborators

4 joint publications

Pamela McKay

3 joint publications

Jessica Okosun

3 joint publications

Andrew J Davies

3 joint publications

Christopher P Fox